Literature DB >> 19344398

CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells.

Lorenzo Brunetti, Rosa Di Noto, Giovanna Abate, Marisa Gorrese, Angela Gravetti, Maddalena Raia, Giulia Scalia, Caterina Pascariello, Andrea Camera, Luigi Del Vecchio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19344398     DOI： 10.1111/j.1365-2141.2009.07644.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  A comprehensive immunophenotypic marker analysis of hairy cell leukemia in paraffin-embedded bone marrow trephine biopsies--a tissue microarray study.

Authors:  Judit Tóth-Lipták; Klára Piukovics; Zita Borbényi; Judit Demeter; Enikő Bagdi; László Krenács
Journal:  Pathol Oncol Res       Date:  2014-06-06       Impact factor: 3.201

Review 2.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

3.  Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.

Authors:  Dalia A Salem; Drake Scott; Catharine S McCoy; David J Liewehr; David J Venzon; Evgeny Arons; Robert J Kreitman; Maryalice Stetler-Stevenson; Constance M Yuan
Journal:  Cytometry B Clin Cytom       Date:  2019-05-11       Impact factor: 3.058

4.  CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.

Authors:  Zhihong Hu; Yi Sun; Ellen J Schlette; Guilin Tang; Shaoying Li; Jie Xu; C Cameron Yin; Ken H Young; Keyur Pravinchandra Patel; Roberto N Miranda; Maitrayee Goswami; Michael Wang; Jeffrey L Jorgensen; L Jeffrey Medeiros; Sa A Wang
Journal:  Mod Pathol       Date:  2017-10-06       Impact factor: 7.842

5.  CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.

Authors:  S J Coles; E C Y Wang; S Man; R K Hills; A K Burnett; A Tonks; R L Darley
Journal:  Leukemia       Date:  2011-01-28       Impact factor: 11.528

6.  Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia.

Authors:  Yi Miao; Lei Fan; Yu-Jie Wu; Yi Xia; Chun Qiao; Yan Wang; Li Wang; Min Hong; Hua-Yuan Zhu; Wei Xu; Jian-Yong Li
Journal:  Oncotarget       Date:  2016-03-22

7.  CD200 Expression in Neuroendocrine Neoplasms.

Authors:  Jason E Love; Kimberly Thompson; Mark R Kilgore; Maria Westerhoff; Claire E Murphy; Antonios Papanicolau-Sengos; Kinsey A McCormick; Veena Shankaran; Natalie Vandeven; Faith Miller; Astrid Blom; Paul T Nghiem; Steven J Kussick
Journal:  Am J Clin Pathol       Date:  2017-09-01       Impact factor: 2.493

Review 8.  CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance.

Authors:  Giovanni D'Arena; Vincenzo De Feo; Giuseppe Pietrantuono; Elisa Seneca; Giovanna Mansueto; Oreste Villani; Francesco La Rocca; Fiorella D'Auria; Teodora Statuto; Luciana Valvano; Francesca Arruga; Silvia Deaglio; Dimitar G Efremov; Alessandro Sgambato; Luca Laurenti
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

Review 9.  CD200:CD200R Interactions and Their Importance in Immunoregulation.

Authors:  Katarzyna Kotwica-Mojzych; Barbara Jodłowska-Jędrych; Mariusz Mojzych
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

Review 10.  NK Cell-Based Immune Checkpoint Inhibition.

Authors:  Muhammad Khan; Sumbal Arooj; Hua Wang
Journal:  Front Immunol       Date:  2020-02-13       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.